US Stock MarketDetailed Quotes
AUTL Autolus Therapeutics
- 2.290
- +0.050+2.23%
Close Dec 20 16:00 ET
- 2.330
- +0.040+1.75%
Post 20:01 ET
609.42MMarket Cap-1.88P/E (TTM)
2.350High2.200Low2.61MVolume2.230Open2.240Pre Close5.96MTurnover1.94%Turnover RatioLossP/E (Static)266.12MShares7.45052wk High1.28P/B307.94MFloat Cap2.20052wk Low--Dividend TTM134.47MShs Float53.240Historical High--Div YieldTTM6.70%Amplitude1.600Historical Low2.280Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Autolus Therapeutics Stock Forum
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
4 MINUTES AGO, 7:30 PM EST
VIA GLOBENEWSWIRE
ya I'm getting in here
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
• AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
• Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
• Conference call to be held on November 11 at 08:30 am EST/13:3...
Abeona Therapeutics ( $Abeona Therapeutics (ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals (RCKT.US)$ ) ...
No comment yet